High prevalence of TB disease in contacts of adults with extrapulmonary TB by Wingfield, Tom et al.
  1Thorax Month 2017 Vol 0 No 0
High prevalence of TB disease 
in contacts of adults with 
extrapulmonary TB
AbstrAct 
UK guidelines no longer recommend 
routine screening of household contacts 
of adult patients with extrapulmonary TB 
(EPTB). From 27 March 2012 to 28 June 
2016, we investigated the prevalence of 
active TB disease in household contacts 
of 1023 EPTB index cases in North West 
England, and compared estimates with: 
published new entrant migrant screening 
programme prevalence (~147/100 000 
person-years); London-based contact 
screening data (700/100 000 contacts 
screened); and National Institute for Health 
and Care Excellence (NICE) new entrant 
TB screening thresholds (TB prevalence 
>40/100 000 people). Active TB disease 
prevalence in EPTB contacts was 440/100 
000 contacts screened, similar to UK new 
entrant screening programmes, London 
EPTB contact prevalence and >10 times 
NICE’s threshold for new entrant screening. 
The decision to no longer recommend 
routine screening of EPTB contacts should 
be re-evaluated and cost-effectiveness 
analyses of screening strategies for EPTB 
contacts should be performed.
IntroductIon
Formalised standardised contact tracing 
for TB has been recommended since 
1983.1 The 2006 and 2011 National 
Institute for Health and Care Excel-
lence (NICE) guidance2 3 recommend 
that ‘Screening should be offered to the 
household contacts of any person with 
active TB irrespective of the site of infec-
tion.’ This recommendation was based on 
five large contact tracing studies, which 
showed high yield of latent TB infection 
(LTBI) and active TB disease, even in 
contacts of patients with extrapulmonary 
TB (EPTB). However, in 2016, NICE no 
longer recommended routine contact 
tracing for household contacts of adults 
with EPTB.4 This decision has been 
questioned by the Joint TB Committee 
of the British Thoracic Society, and did 
not include published UK data from 
Edinburgh5 and Birmingham,6 which 
showed high rates of LTBI and active TB 
disease in EPTB contacts.
To examine the potential impact of the 
NICE 2016 recommendations on popu-
lation TB case detection, we calculated 
the yield of active TB disease among 
household contacts of EPTB index 
cases, and compared this with recently 
published data from UK new-entrant 
migrant screening programmes and a 
descriptive study of contact screening in 
London.
Methods
study design
A population-based retrospective study.
data source
Data were collected using Public Health 
England’s Enhanced TB Surveillance 
(ETS) system, supplemented with data 
from systematic multidisciplinary review 
during North West TB cohort audit.7 8
eligibility criteria
Participants were adult (≥18 years-old) 
residents of North West England noti-
fied to Public Health England ETS with 
microbiologically or clinically confirmed 
EPTB disease from 27 March 2012 to 28 
June 2016, and who had ≥1 household 
contact, but were not part of a TB cluster 
(<25 contacts identified).
outcomes
Primary outcomes
The primary outcome was prevalence of 
active TB disease in contacts of eligible 
patients. Prevalence was calculated as 
the number of contacts identified to have 
active TB disease divided by the total 
number of contacts screened during the 
study period. Number needed to screen 
(NNS) to detect one case of active TB 
disease was derived from the preva-
lence. To adjust for potential impact of 
new entrant screening programmes, a 
sensitivity analysis was also performed 
that included only contacts of UK-born 
patients with EPTB.
Secondary outcomes
NNS and prevalence of LTBI and positive 
screening outcome (the sum of LTBI and 
active TB disease) in contacts of eligible 
patients were also estimated. Finally, we 
compared prevalence estimates from 
North West England with those obtained 
from UK new-entrant migrant screening 
programmes,9 recommended thresholds 
for screening of new entrants to the UK in 
NICE 2016 TB guidelines,4 and a recent 
descriptive study of contact tracing from 
the London area.10
statistical analysis
Proportions of contacts who had active 
TB disease, LTBI or a positive screening 
outcome in LTBI were summarised with 
CIs and compared between groups: 
UK-born versus non-UK-born long-term 
(above cohort median years since entry to 
UK) migrants versus non-UK-born recent 
(below cohort median years) migrants; 
and mediastinal lymph node or pleural 
TB versus other site of EPTB,10 using 
χ2 test for trend.
All statistical analyses were performed 
using Stata V.12 (StataCorp, College 
Station, Texas).
ethical approval
This study used anonymised routinely 
collected public health surveillance data 
and individual participant assent was not 
sought. 
results
Between 27 March 2012 and 28 June 
2016, up to 1026 (51%) index cases with 
EPTB met eligibility criteria, and had a 
total of 3652 household contacts screened 
(median 3; IQR 2–5).
The prevalence of active TB disease, 
LTBI and positive screening outcome 
in EPTB contacts was 0.44% (95% CI 
0.2 to 0.6), 3.6% (95% CI 2.7 to 4.5) and 
4.0% (95% CI 3.1 to 4.9), respectively 
(figure 1). To detect one positive screening 
outcome, 25 contacts of EPTB cases would 
need to be screened (figure 1).
Eligible contacts of patients who were 
recent migrants to the UK (less than 
median duration of years since entry) 
compared with patients who were long-
term migrants or UK born had higher 
prevalence of active TB disease (recent 
migrants 0.78% (0.13–1.4) vs long-term 
migrants 0.29% (0.0–0.6) vs UK born 
0.16% (0.0–0.4), χ2 test for trend 
P<0.001, figure 1) and LTBI (5.9% (4.0–
7.8) vs 2.3% (1.3–3.3) vs 1.6% (0.4–2.7), 
figure 1).
There was no significant difference 
between prevalence of active TB disease, 
LTBI or positive screening outcome in 
contacts of patients with pleural and 
isolated mediastinal lymphadenopathy 
versus contacts of patients with EPTB at 
other sites (figure 2).
dIscussIon
The NICE 2016 TB guidelines no longer 
recommend routine screening for EPTB 
contacts, citing a lack of cost-effectiveness. 
However, our data from North West 
England, a low TB burden region, show 
that prevalence of active TB disease 
among all household contacts was high 
at 440 per 100 000, and was 167 per 
100 000 when analysis was limited to 
contacts of UK-born EPTB cases. These 
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Figure 1 Prevalence of latent TB infection (LTBI), active TB disease and positive screening outcome in extrapulmonary TB (EPTB) contacts overall 
and by place of birth and entry to UK (n=1026). Detection rate is the number of cases of LTBI, active TB disease or positive screening outcome 
detected per 100 000 contacts screened. NNS is the number of patients needed to screen to detect one case of LTBI, active TB disease or a positive 
screening outcome in their screened contacts. Error bars represent 95% CIs and the P value is derived from χ2 test for trend comparing prevalence of 
LTBI, active TB disease and positive screening outcome in contacts of patients born in UK, born abroad with less recent entry and born abroad with 
recent entry (all P<0.001). Up to 946 of 1026 patients with EPTB had data available on country of birth and time in UK.
Figure 2 Prevalence of latent TB infection (LTBI), active TB disease and positive screening outcome in extrapulmonary TB (EPTB) contacts of patients 
with pleural or isolated mediastinal lymph node TB versus other sites of EPTB (n=1026). Detection rate is the number of cases of LTBI, active TB 
disease or positive screening outcome detected per 100 000 contacts screened. NNS is the number of patients needed to screen to detect one case of 
LTBI, active TB disease or a positive screening outcome in their screened contacts. Error bars represent 95% CIs and the P value is derived from   
χ2 test comparing prevalence of LTBI, active TB disease and positive screening outcome in contacts of patients with pleural or isolated mediastinal 
lymph node TB versus other sites of EPTB (P=0.2).
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data strongly suggest that screening of 
household contacts of EPTB cases could 
have substantial individual and public 
health benefits, and with recent data 
from London demonstrating similar 
findings, we urge that NICE guidance is 
reconsidered.
The active TB disease point prevalence 
we found is similar to a recent review of UK 
pre-entrant screening programmes (147 
per 100 000 person-years),9 a London-
based contact tracing study (700/100 000 
contacts screened)10 and 10 times higher 
than that suggested by 2016 NICE 
guidelines as the country prevalence 
threshold for UK new entrant screening 
(>40 per 100 000 people per year).4
This study has some limitations. First, 
ETS data were collected retrospec-
tively, meaning that despite regional 
data cleaning, some data may be 
missing or inaccurate. Second, despite 
complementary results to those from 
the London-based cohort,10 the North 
West population of TB-affected people 
may not be generalisable to the rest of 
England.
In conclusion, our findings show that 
the yield of active TB disease in EPTB 
contacts is substantially greater than the 
threshold advocated by NICE for new 
entrant screening and similar to that 
of a large London-based cohort. This 
suggests that, in England, the 2016 deci-
sion by NICE to no longer recommend 
routine EPTB contact tracing should be 
re-evaluated, including through studies 
of cost-effectiveness.
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